Floatz logo

rd14-01

Mantle Cell Lymphoma

He HuangEarly Phase 1Active
C
34/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
24/ 100
Competitive Position
65/ 100

Competitive context

105 Active assets in the Mantle Cell Lymphoma cohort.

Asset / SponsorPhaseRating
Inno-206
National Cancer Institute (NCI)
Phase 4BB
Cyclophosphamide
Miltenyi Biomedicine GmbH
Phase 4BB
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
City of Hope Medical Center
Phase 4BB
PREDNISONE TABLETS
National Cancer Institute (NCI)
Phase 4BB
(+)-VINCRISTINE
National Cancer Institute (NCI)
Phase 4BB

View all 50 →

Same molecule, other indications

rd14-01 is also rated in:

neoplasmDormant
CC
Indicative ·
45 / 100
View asset →
Diffuse Large B-cell LymphomaDormant
C
Indicative ·
36 / 100
View asset →
Follicular LymphomaDormant
C
Indicative ·
34 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →